Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 22, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 39,625 shares of common stock to 4 new employees.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $12.24 the fair market value on December 30, 2011, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option was effective as of December 30, 2011, and also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin i
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
4. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
5. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
8. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... DENVER , Aug. 28, 2014 ... a two-year investment into this game-changing method for ... Today, clinical trials target specific cancers, ... be contributing factors for the cancer, in the ... is that this information may not be well ...
(Date:8/28/2014)... 28, 2014  In anticipation of the upcoming MEDevice ... available for the first time. Industry Overview: Medtech & ... offers a snapshot of San Diego,s ... from the latest employment statistics to current venture capital investment ... Diego such a vital part of the global ...
(Date:8/28/2014)... MINNEAPOLIS , Aug. 28, 2014 Nonin ... a leader in noninvasive medical monitoring, today announced that ... Nonin Model 3231 OEM/eHealth finger pulse oximeter for use ... finger pulse oximeter plugs into a telemedicine hub or ... and pulse rate in pediatric to adult patients. The ...
Breaking Medicine Technology:Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... Weiss, Director of Maryland Laser, Skin and Vein,Institute, ... BALTIMORE, Oct. 2 Robert Weiss, M.D., board ... U.S. to offer his,patients DOT Therapy (Dermal Optical ... Dr. Weiss is an,internationally renowned dermatologist, who is ...
... Biotechnologies AB and Dyax,Corp. (NASDAQ: DYAX ) ... a,collaboration to discover and to develop therapeutic ... inflammatory diseases., The collaboration follows the ... Professors Frostegard and de Faire of the ...
Cached Medicine Technology:DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4
(Date:8/28/2014)... 2014) Solid-head power toothbrushes retain less bacteria ... The University of Texas Health Science Center at ... the study are published in the August issue ... and professor at the UTHealth School of Dentistry, ... counts were lower in the solid-head toothbrush group ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ISI ... management solutions, will be sponsoring the 2014 Presidio ... annual event allows Presidio leadership to engage with ... year. Specifically, they will be rolling out objectives ... , While at the event, ISI will be ...
(Date:8/28/2014)... A candidate Ebola vaccine could be given to healthy ... early as September, as part of an series of ... disease that has killed more than 1,400 people in ... of this candidate vaccine, being co-developed by the US ... be accelerated with funding from an international consortium in ...
(Date:8/28/2014)... prevent Ebola virus disease will begin next week by ... part of the National Institutes of Health. , The ... vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will ... an immune system response in healthy adults. Testing will ... Maryland. , The study is the first of several ...
(Date:8/28/2014)... People aged 70 and over who identify themselves as ... where they perceive they have lower value than younger ... University of Kent, titled ,Being old and ill, across ... subjective health, used data from the European Social Survey. ... asked to self-rate their health., The researchers found that ...
Breaking Medicine News(10 mins):Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5
... become one of the major public health problems in developed ... a researcher at the University of Zaragoza (UNIZAR), tells SINC. ... than two hours of television per day. At weekends, this ... July issue of the journal Preventive Medicine , show ...
... HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay News) -- ... -- also known as cryotherapy -- works better than applying ... No one treatment cured more than half of cases, ... needed, experts say. The new finding is a bit ...
... Round Rock, Texas is recruiting patients for a Phase ... recurrence in previously treated patients. The trial will ... Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung ... Cell LunG Cancer Immunotherapy) study is expected to be ...
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. 16 ... risk of colorectal cancer, new research finds. Prior research ... colon cancer. But this study is among the first to ... side effects such as gastrointestinal bleeding -- may also be ...
... patients develop post-traumatic stress syndrome (PTSD) after the trauma ... to be exacerbated by delusional or fragmentary memories of ... writing in BioMed Central,s open access journal Critical ... relatives make a diary for patients, featuring information about ...
... significant and lasting relief for patients with myelofibrosis, a ... University of Texas MD Anderson Cancer Center report in ... . Myelofibrosis is caused by the accumulation of ... scarring the bone marrow and limiting its ability to ...
Cached Medicine News:Health News:Teenagers are more sedentary on weekends 2Health News:For Common Warts, Freezing Therapy Works Best: Study 2Health News:For Common Warts, Freezing Therapy Works Best: Study 3Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3Health News:Intensive care diaries protect patients from PTSD 2Health News:JAK inhibitor provides rapid, durable relief for myelofibrosis patients 2Health News:JAK inhibitor provides rapid, durable relief for myelofibrosis patients 3
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Straight heavy shafts with delicate 7 mm tying platform. Sharp pointed tips for removing fine sutures. Wide serrated handle with polished finish. Overall length 4.1 inches....
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Curved, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Medicine Products: